EFFECTS OF SMOKING AND SMOKING CESSATION ON ENDOTHELIAL FUNCTION: ONE-YEAR OUTCOMES FROM A RANDOMIZED CLINICAL TRIAL  by Gossett, Linda K. et al.
A153.E1435
JACC Maarch 9, 2010
Volume 55, issue 10A
 VASCULAR DISEASE
EFFECTS OF SMOKING AND SMOKING CESSATION ON ENDOTHELIAL FUNCTION: ONE-YEAR OUTCOMES 
FROM A RANDOMIZED CLINICAL TRIAL
ACC Oral Contributions
Georgia World Congress Center, Room B403
Monday, March 15, 2010, 5:00 p.m.-5:15 p.m.
Session Title: Modulators of Endothelial Dysfunction
Abstract Category: Vascular--Pathophysiology—Clinical
Presentation Number: 0915-05
Authors: Linda K. Gossett, Megan E. Piper, Heather M. Johnson, Susan E. Aeschlimann, Claudia E. Korcarz, Timothy B. Baker, Michael C. Fiore, James 
H. Stein, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background: The long-term effects of continued smoking and smoking cessation on endothelial function have not been described previously. We 
hypothesized that smoking cessation would improve flow-mediated dilation (FMD) of the brachial artery (BA), a measure of endothelial function.
Methods: This was a 1 year, prospective, double-blind, randomized, placebo-controlled clinical trial of the effects of 6 smoking cessation 
interventions. BA FMD was measured by B-mode ultrasound before starting on smoking cessation therapy and 1 year after the target quit date. 
Smoking cessation was verified by exhaled carbon monoxide levels. ΔFMD was compared between arms and between subjects that successfully quit 
smoking (QUIT) and those who continued to smoke (CONT). Predictors of FMD and ΔFMD were identified by multivariable regression.
Results: The 1,504 current smokers (58% female, 84% white) were mean (standard deviation): 44.7 (11.1) years old, smoked 21.4 (8.9) 
cigarettes/day and had a smoking burden of 29.4 (20.4) pack-years. Baseline FMD was 6.2% (4.4%) and was similar in each treatment arm. 
After controlling for BA diameter, site and reader, baseline FMD was predicted by pack-years (p=0.009), triglycerides (p=0.009), and high-density 
lipoprotein cholesterol (p=0.041). After one year, 25.3% successfully QUIT. Their FMD increased by 1.0% (4.3%, p=0.005) in QUIT and did not change 
in CONT (p=0.643). ΔFMD did not differ by treatment arm (p=0.499) and remained significant after controlling for change in BA diameter, site, and 
reader (p=0.011) and was not affected by changes in waist circumference or C-reactive protein.
Conclusions: This was the first, prospective randomized clinical trial to demonstrate that smoking cessation leads to prolonged improvements in 
endothelial function. Improved endothelial function may mediate part of the reduced cardiovascular disease risk observed within 1 year of smoking 
cessation.
